IMPROVE
28.9.2021 14:03:13 CEST | Business Wire | Press release
The Improving Patient Outcomes (ImPrOve) Think Tank, a group of anaesthetists, surgeons and patient representatives, today launched its European Report to address a serious public health issue – death and serious complication rates in the 30-days after high-risk surgery remain high.i In an effort to improve patient safety and outcomes, the Report calls for better physician training on the latest guidelines, funding for modern digital monitoring, greater use of data from modern technologies in health policies and the right for patients to be involved in dialogue about the management of their procedure.
In Europe, 2.4 million patients undergo high-risk surgery every year.ii,iii Evidence from the UK suggests that 80% of postoperative deaths occur in a 10% sub-population of high-risk patients. If this trend continued at a European level, potentially 192,000 will die in the 30-day period after surgery.i While there are many challenges in high-risk surgery, the most alarming complication for the ImPrOve Think Tank is haemodynamic instability, manifested as drops in blood pressure, and known as IOH.i
During high-risk surgery it is vital that blood continues to flow to organs. IOH is common during surgery under general anaesthesia, occurring in up to 99% of patients.i It has the potential to cause tissue damage in any vital organ, but the heart and kidneys are most affected. Recent studies show associations between IOH and increased risk of acute kidney injury (AKI) and myocardial injury iv,v – the leading cause of post-operative mortality.
Postsurgical patients with AKI and myocardial injury stay longer in hospital, have higher readmission rates, and cost more to care for.iv The subsequent financial impact of this also has a significant impact on European healthcare systems. However, if haemodynamic instability is effectively monitored and prevented, these serious complications can be avoided, and patient outcomes can be significantly improved.
“Our mission is to work collaboratively with patient representatives, clinicians and policy makers to improve perioperative patient safety and experience with the help of advanced haemodynamic monitoring technologies”, commented Professor Olivier Huet, ImPrOve Chair and Professor of Anaesthesia and Intensive Care Medicine. “Major gaps still exist in reducing the risk of complications after high-risk surgery across European hospitals, working together is therefore imperative. All stakeholders need to be onboard so that we can create change and address the calls to action.”
By 2050, it is predicted that 1 in 4 people could be over 65.vi With haemodynamic instability reported as high as 83% in more senior patients,vii the ImPrOve Think Tank believe it will be a likely cause of a significant proportion of modifiable postoperative mortality and morbidity in Europe.
“Patients are often unaware of the risks of not receiving innovative digital monitoring technology, so they may not ask for the best perioperative management”, said Ms Luciana Valente, International Relations Manager at SIHA, Italy, and member of the Think Tank. “It is essential that patients are better informed of the key risks associated with their procedure and aware that the use of innovative digital monitoring, and other actions will be taken to mitigate these risks. The more a patient is invested in a procedure, the better the outcomes will be.”
For further information and to download ‘Improving patient safety: why perioperative care and effective monitoring matters” please visit www.improvethinktank.org
References
i Pearse RM, Moreno RP, Bauer P, Pelosi P, Metnitz P, Spies C et al . Mortality after surgery in Europe: a 7-day cohort study. Lancet. 2021; Sep 22;380(9847):1059-65. Available at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61148-9/fulltext [accessed July 2021].
ii Preoperative Score to Predict Postoperative Mortality – POSPOM Edward’s Presentation
iii Ghaferi, et al. Variation in Hospital Mortality Associated with Inpatient Surgery. N Engl J Med, 2009.
iv Keuffel EL, Rizzo J, Stevens M, Gunnarsson C, Maheshwari K. Hospital costs associated with intraoperative hypotension among non-cardiac surgical patients in the US: a simulation model. J Med Econ. 2019 Jul;22(7):645-651. Available at: https://www.tandfonline.com/doi/full/10.1080/13696998.2019.1591147 [accessed July 2021]
v Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anaesth. 2018 Oct;121(4):706-721. Available at: https://bjanaesthesia.org/article/S0007-0912(18)30376-3/fulltext . [accessed July 2021].
vi United Nations. Ageing. 2019. Available at: https://www.un.org/en/sections/issues-depth/ageing/ [accessed July 2021]
vii Wickham A, Highton D, Martin D, The Pan London Perioperative Audit and Research Network. Care of elderly patients: a prospective audit of the prevalence of hypotension and the use of BIS intraoperatively in 25 hospitals in London. Perioper Med (Lond). 2016; 5: 12. Available at: (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882849/ ) [accessed July 2021].
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005621/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
